Table 3 The percentage VEGFR-2 inhibitory properties of the tested compounds at 10 μM.
Compd | HCT116 | PaCa2 | MCF7 | |||
|---|---|---|---|---|---|---|
pg/mL ± SEM | % Inhibition | pg/mL ± SEM | % Inhibition | pg/mL ± SEM | % Inhibition | |
17a | 38.20 ± 1.6 | 88.0 | 19.26 ± 1.0 | 94.1 | 51.50 ± 0.8 | 80.1 |
17b | 73.25 ± 2.0 | 77.0 | 38.75 ± 1.4 | 88.1 | 77.20 ± 0.6 | 70.2 |
17c | 44.50 ± 1.1 | 86.0 | 28.43 ± 1.0 | 91.3 | 60.40 ± 0.5 | 76.7 |
17d | 87.40 ± 1.9 | 72.5 | 53.42 ± 0.7 | 83.7 | 72.80 ± 1.2 | 71.9 |
17e | 107.50 ± 2.0 | 66.2 | 127.43 ± 1.3 | 61.0 | 116.50 ± 1.0 | 55.0 |
17f | 43.70 ± 0.9 | 86.2 | 27.53 ± 1.1 | 91.6 | 63.20 ± 0.9 | 75.6 |
17g | 98.40 ± 1.2 | 69.0 | 72.80 ± 0.9 | 77.7 | 64.80 ± 0.5 | 75.0 |
17h | 51.74 ± 1.5 | 83.7 | 18.25 ± 0.6 | 94.4 | 52.70 ± 0.7 | 79.6 |
17i | 81.40 ± 1.9 | 74.4 | 42.76 ± 0.7 | 86.9 | 49.50 ± 0.3 | 80.9 |
17j | 62.50 ± 0.7 | 80.3 | 24.78 ± 0.3 | 92.4 | 44.80 ± 0.6 | 82.7 |
17k | 67.80 ± 1.3 | 78.7 | 76.40 ± 0.9 | 76.6 | 86.40 ± 0.5 | 66.6 |
17l | 84.20 ± 1.5 | 73.5 | 86.45 ± 1.2 | 73.5 | 73.50 ± 0.8 | 71.6 |
17m | 44.50 ± 0.5 | 86.0 | 25.36 ± 1.0 | 92.2 | 42.80 ± 0.4 | 83.5 |
17n | 115.30 ± 2.2 | 63.7 | 40.70 ± 1.6 | 87.5 | 85.60 ± 0.7 | 66.9 |
17o | 48.40 ± 0.6 | 84.8 | 31.64 ± 1.9 | 90.3 | 38.70 ± 0.4 | 85.0 |
17p | 31.80 ± 0.8 | 90.0 | 21.76 ± 0.4 | 93.3 | 48.30 ± 0.4 | 81.3 |
17q | 132.30 ± 0.9 | 58.4 | 135.70 ± 1.7 | 58.5 | 145.70 ± 1.9 | 43.7 |
17r | 67.34 ± 0.4 | 78.8 | 66.53 ± 0.8 | 79.6 | 84.30 ± 1.0 | 67.4 |
17s | 53.80 ± 0.9 | 83.1 | 26.50 ± 0.5 | 91.9 | 47.60 ± 0.6 | 81.6 |
17t | 124.70 ± 1.3 | 60.8 | 115.00 ± 0.9 | 64.8 | 96.70 ± 1.2 | 62.6 |
Sunitinib | 38.50 ± 1.0 | 87.9 | 45.30 ± 0.2 | 86.1 | 48.70 ± 1.0 | 81.2 |
Control | 317.80 ± 3.5 | – | 326.80 ± 1.9 | – | 258.70 ± 2.3 | – |
